First-line treatment with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has been shown to improve survival over gemcitabine in patients with metastatic pancreatic cancer, but FOLFIRINOX also increases neurotoxicity. Read more . . .
A sequential treatment strategy proved less effective than a maintenance strategy for patients with metastatic pancreatic cancer (mPC) in a phase 2 trial published in the Journal of Clinical Oncology.